Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida. Show more
501 E. Las Olas Blvd., Fort Lauderdale, FL, 33301, United States
Market Cap
6.054M
52 Wk Range
$1.67 - $6.20
Previous Close
$2.52
Open
$2.56
Volume
8,466
Day Range
$2.47 - $2.56
Enterprise Value
4.813M
Cash
1.385M
Avg Qtr Burn
-552K
Insider Ownership
14.11%
Institutional Own.
5.97%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
TCR-T targeting neoantigens Details Cancer, Solid tumor/s | Failed Discontinued |
